Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies and tends to be relatively resistant to conventional therapies. Activated Ras oncogene mutations are found in up to 90% of PDAC, leading to activation of the Ras/Raf/MEK/ERK signaling pathway. Sorafe...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Niranjan, Zhang, Changhua, Hinz, Stefan, Schwarz, Margaret A, Schwarz, Roderich E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618297/
https://www.ncbi.nlm.nih.gov/pubmed/23497499
http://dx.doi.org/10.1186/1756-9966-32-12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618297/
https://www.ncbi.nlm.nih.gov/pubmed/23497499
http://dx.doi.org/10.1186/1756-9966-32-12

Ejemplares similares